Litcius/Paper detail

The association of spirometric small airways obstruction with respiratory symptoms, cardiometabolic diseases, and quality of life: results from the Burden of Obstructive Lung Disease (BOLD) study

Ben Knox‐Brown, Jaymini Patel, James Potts, Rana Ahmed, Althea Aquart-Stewart, Cristina Bárbara, A. Sonia Buist, Hamid Hacene Cherkaski, Meriam Denguezli, M. Elbiaze, Gregory E. Erhabor, Frits M.E. Franssen, Mohammed Al Ghobain, Þórarinn Gíslason, Christer Janson, Ali Kocabaş, David M. Mannino, Guy B. Marks, Kevin Mortimer, Asaad Ahmed Nafees, Daniel Obaseki, Stefanni Nonna M Paraguas, Li Cher Loh, Abdul Rashid, Sundeep Salvi, Terence Seemungal, Michael Studnicka, Wan C. Tan, Emiel F.�M. Wouters, Hazim Abozid, Alexander Mueller, Peter Burney, André F.S. Amaral

2023Respiratory Research21 citationsDOIOpen Access PDF

Abstract

Abstract Background Spirometric small airways obstruction (SAO) is common in the general population. Whether spirometric SAO is associated with respiratory symptoms, cardiometabolic diseases, and quality of life (QoL) is unknown. Methods Using data from the Burden of Obstructive Lung Disease study (N = 21,594), we defined spirometric SAO as the mean forced expiratory flow rate between 25 and 75% of the FVC (FEF 25-75 ) less than the lower limit of normal (LLN) or the forced expiratory volume in 3 s to FVC ratio (FEV 3 /FVC) less than the LLN. We analysed data on respiratory symptoms, cardiometabolic diseases, and QoL collected using standardised questionnaires. We assessed the associations with spirometric SAO using multivariable regression models, and pooled site estimates using random effects meta-analysis. We conducted identical analyses for isolated spirometric SAO (i.e. with FEV 1 /FVC ≥ LLN). Results Almost a fifth of the participants had spirometric SAO (19% for FEF 25-75 ; 17% for FEV 3 /FVC). Using FEF 25-75, spirometric SAO was associated with dyspnoea (OR = 2.16, 95% CI 1.77–2.70), chronic cough (OR = 2.56, 95% CI 2.08–3.15), chronic phlegm (OR = 2.29, 95% CI 1.77–4.05), wheeze (OR = 2.87, 95% CI 2.50–3.40) and cardiovascular disease (OR = 1.30, 95% CI 1.11–1.52), but not hypertension or diabetes. Spirometric SAO was associated with worse physical and mental QoL. These associations were similar for FEV 3 /FVC. Isolated spirometric SAO (10% for FEF 25-75 ; 6% for FEV 3 /FVC), was also associated with respiratory symptoms and cardiovascular disease. Conclusion Spirometric SAO is associated with respiratory symptoms, cardiovascular disease, and QoL. Consideration should be given to the measurement of FEF 25-75 and FEV 3 /FVC, in addition to traditional spirometry parameters.

Topics & Concepts

MedicineSpirometryWheezeInternal medicineCOPDVital capacityObstructive lung diseasePopulationChronic coughAsthmaPhysical therapyLungDiffusing capacityLung functionEnvironmental healthChronic Obstructive Pulmonary Disease (COPD) ResearchAsthma and respiratory diseasesRespiratory Support and Mechanisms